Efficacy and Safety of Sodium Heparin (Eurofarma)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to verify, through a randomized, single-blind, multicentre, parallel and comparative study, the effectiveness of heparin sodium of porcine origin in patients undergoing heart surgery at that require the aid of cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on the strengths of markers of coagulation TCA, TTPA, Anti-Xa, heparin bioavailable and loss of excessive blood (bleeding) at the end of the surgery.

Official Title
-----------------
Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass

Conditions
-----------------
Cardiac Surgery

Intervention / Treatment
-----------------
* Biological: heparin sodium - Eurofarma
* Biological: heparin sodium - APP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who agree with all aspects of the study and sign the FICT; Patients of both sexes; Patients aged above 18 years; Patients with cardiac surgery and requiring movement; AND Extracorporeal. Exclusion Criteria: Patients with hematological disorders that compromise the surgical changes (eg myeloproliferative syndromes, anemia Hb <11.0 g / dL, Platelets < 150,000 mm3); Patients with disorders of hemostasis (INR> 1.40) (rTTPA> 1.40); Patients with renal dysfunction (creatinine> 1.50); Patients with deep hyperthermia; Liver disease (AST and ALT> 2 times that of the reference value); Patients with a history of allergy to heparin or protamine; Patients with history of heparin-induced thrombocytopenia; Tables infection (eg endocarditis, infection of immune human (HIV), hepatitis B and C, septicemia and pneumonia); Reoperations; Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days; Use of acetylsalicylic acid is less than 5 days; Use of low molecular weight heparin for less than 24 hours; OR Use of non-fractioned heparin for less than 12 hours.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Heparin sodium - Eurofarma | Biological: heparin sodium - Eurofarma<br>* Heparin sodium 5.000 UI - Eurofarma<br>|
| Active Comparator: 2<br>Heparin APP | Biological: heparin sodium - APP<br>* Heparin sodium APP 5.000 USP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of TTPA, Anti-Xa and ACT |  | Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative | 
| Comparison of bleeding |  | Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse reactions |  | Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heparin cardiac surgery